Eiger BioPharmaceuticals EBIT

The latest EBIT for EIGR is $-71M as of December 2023. That compares with $-93M in the prior-year period — up 23.7% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Eiger BioPharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, EIGR's EBIT moved from $-93M to $-71M — a 23.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Eiger BioPharmaceuticals's operating scale or balance-sheet position.

Against Healthcare companies, EIGR currently prints $-71M for EBIT, while the sector average sits near $22B. That is roughly 100.3% below the sector mean. Large gaps often invite a closer look at Eiger BioPharmaceuticals's growth, margins, and balance sheet.

A EBIT figure of $-71M for EIGR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting EIGR's EBIT ($-71M), review year-over-year change from $-93M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.